Overview
Background
Dr Mollee practices as a consultant haematologist in clinical and laboratory haematology at the Princess Alexandra Hospital and is Associate Professor with the University of Queensland Medical School.
Having trained in Brisbane and Toronto, Dr Mollee has developed an international reputation studying amyloidosis and the plasma cell dyscrasias. He holds appointments with the Medical Scientific Advisory Group of Myeloma Australia, Australian Amyloidosis Network, National Blood Cancer Taskforce and is a member of the AACB Monoclonal Gammopathy Working Group and the International Kidney & Monoclonal Gammopathy Research Group. He is a past Chairman of the Australasian Leukaemia and Lymphoma Group (ALLG) and current Chair of the Australian Amyloidosis Network. He heads the Myeloma Service as well as the Queensland Amyloidosis Centre which runs one of the few clinics in Australia dedicated exclusively to the care of patients with amyloidosis.
Availability
- Associate Professor Peter Mollee is:
- Available for supervision
Qualifications
- Masters (Coursework) of Medical Science, University of Newcastle
- Royal Australasian College of Physicians, Royal Australasian College of Physicians
- Royal College of Pathologists of Australasia, Royal College of Pathologists of Australasia
Research impacts
The research of the Queensland Amyloidosis Centre aims to improved the diagnosis, monitoring and therapy of all types of amyloidosis. The Centre, in collaboration with Pathology Queensland and the Translational Research Institute, developed laser capture macrodisscution and tandem mass spectrometry analysis to accurately diagnosis the type of amyloidosis that patients have and have introuduced this assay into the clinical laboratory. Research to improve the diagnosis and monitoring of this rare disease has also assessed immunoglobulin free light chain assays, bone scintigraphy and novel radionuclide PET tracers. The Queensland Amyloidosis Centre maintains an active clinical trial program in amyloidosis therapies including both investigator-initiated and commercial studies.
Works
Search Professor Peter Mollee’s works on UQ eSpace
2013
Conference Publication
Immunosuppression (IST) Can Be Safely Ceased During Chemotherapy For Post-Transplant Lymphoproliferative Disorders (PTLD) In Renal Transplant Patients
Taylor, Emma, Jones, Mark, Hourigan, Matthew J., Johnson, David W., Gill, Devinder S., Isbel, Nicole, Hawley, Carmel M., Marlton, Paula, Gandhi, Maher K., Campbell, Scott B. and Mollee, Peter (2013). Immunosuppression (IST) Can Be Safely Ceased During Chemotherapy For Post-Transplant Lymphoproliferative Disorders (PTLD) In Renal Transplant Patients. 55th Annual Meeting of the American Society of Hematology, New Orleans, LA United States, 7-10 December 2013. Washington, DC United States: American Society of Hematology.
2012
Conference Publication
Intensive chemotherapy for acute myeloid leukemia in elderly patients
Jackson, Kathryn A, Kennedy, Glen A, Mollee, Peter and Morris, Kirk (2012). Intensive chemotherapy for acute myeloid leukemia in elderly patients. 54th ASH Annual Meeting, Atlanta, GA, 8-11 December 2012. American Society of Hematology. doi: 10.1182/blood.v120.21.4341.4341
2012
Conference Publication
Clinical comparison of the freelite and n-latex serum free light chain (FLC) assays in the diagnosis and monitoring of AL amyloidosis
Mapp, Sally, Tate, Jill, Pretorius, Carel and Mollee, Peter (2012). Clinical comparison of the freelite and n-latex serum free light chain (FLC) assays in the diagnosis and monitoring of AL amyloidosis. 54th ASH Annual Meeting, Atlanta, GA, 8-11 December 2012. American Society of Hematology. doi: 10.1182/blood.v120.21.4991.4991
2012
Conference Publication
Outcomes and prognostic factors for patients with acute myeloid leukemia admitted to the intensive care unit
Jackson, Kathryn A., Mollee, Peter, Morris, Kirk, Jackson, Dwane L., Kruger, Peter, Klein, Kerenaftali and Kennedy, Glen A. (2012). Outcomes and prognostic factors for patients with acute myeloid leukemia admitted to the intensive care unit. 54th ASH Annual Meeting, Atlanta, GA United States, 8-11 December 2012. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v120.21.3613.3613
2012
Journal Article
Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma
Keane, C., Nourse, J. P., Crooks, P., Nguyen-Van, D., Mutsando, H., Mollee, P., Lea, R. A. and Gandhi, M. K. (2012). Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma. Internal Medicine Journal, 42 (10), 1113-1119. doi: 10.1111/j.1445-5994.2011.02587.x
2012
Journal Article
CCL2 and CXCL2 enhance survival of primary chronic lymphocytic leukemia cells in vitro
Burgess, Melinda, Cheung, Catherine, Chambers, Lynne, Ravindranath, Karunya, Minhas, Gunjeet, Knop, Louise, Mollee, Peter, McMillan, Nigel A. J. and Gill, Devinder (2012). CCL2 and CXCL2 enhance survival of primary chronic lymphocytic leukemia cells in vitro. Leukemia and Lymphoma, 53 (10), 1988-1998. doi: 10.3109/10428194.2012.672735
2012
Journal Article
Gamma-delta T-cell lymphoma with CNS involvement presenting with proptosis: A case study workup, treatment and prognosis
Sugnanam, K., Ooi, L., Mollee, P. and Vu, P. (2012). Gamma-delta T-cell lymphoma with CNS involvement presenting with proptosis: A case study workup, treatment and prognosis. Orbit, 31 (5), 364-366. doi: 10.3109/01676830.2012.711411
2012
Journal Article
A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis
Mollee, Peter, Tiley, Campbell, Cunningham, Ilona, Moore, John, Prince, H.Miles, Cannell, Paul, Gibbons, Steve, Tate, Jill, Paul, Sanjoy, Fan, Helen Mar and Gill, Devinder S. (2012). A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis. British Journal of Haematology, 157 (6), 766-769. doi: 10.1111/j.1365-2141.2012.09080.x
2012
Journal Article
Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity
Lane, Steven, Gill, Devinder, McMillan, Nigel A. J., Saunders, Nicholas, Murphy, Rachel, Spurr, Terrence, Keane, Colm, Fan, Helen Mar and Mollee, Peter (2012). Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity. Leukemia & Lymphoma, 53 (6), 1077-1083. doi: 10.3109/10428194.2011.642302
2012
Journal Article
Continuous lenalidomide treatment for newly diagnosed multiple myeloma
Palumbo, Antonio, Hajek, Roman, Delforge, Michel, Kropff, Martin, Petrucci, Maria Teresa, Catalano, John, Gisslinger, Heinz, Wiktor-Jędrzejczak, Wiesław, Zodelava, Mamia, Weisel, Katja, Cascavilla, Nicola, Iosava, Genadi, Cavo, Michele, Kloczko, Janusz, Bladé, Joan, Beksac, Meral, Spicka, Ivan, Plesner, Torben, Radke, Joergen, Langer, Christian, Ben Yehuda, Dina, Corso, Alessandro, Herbein, Lindsay, Yu, Zhinuan, Mei, Jay, Jacques, Christian, Dimopoulos, Meletios A., MM-015 Investigators and Mollee, Peter (2012). Continuous lenalidomide treatment for newly diagnosed multiple myeloma. The New England Journal of Medicine, 366 (19), 1759-1769. doi: 10.1056/NEJMoa1112704
2012
Journal Article
Recommendations for standardized reporting of protein electrophoresis in Australia and New Zealand
Tate, Jillian, Caldwell, Grahame, Daly, James, Gillis, David, Jenkins, Margaret, Jovanovich, Sue, Martin, Helen, Steele, Richard, Wienholt, Louise and Mollee, Peter (2012). Recommendations for standardized reporting of protein electrophoresis in Australia and New Zealand. Annals of Clinical Biochemistry, 49 (3), 242-256. doi: 10.1258/acb.2011.011158
2012
Journal Article
WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation
Gray, James X., McMillen, Lyle, Mollee, Peter, Paul, Sanjoy, Lane, Steven, Bird, Robert, Gill, Devinder, Saal, Russell and Marlton, Paula (2012). WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation. Leukemia Research, 36 (4), 453-458. doi: 10.1016/j.leukres.2011.09.005
2012
Journal Article
Validation of whole blood impedance aggregometry as a new diagnostic tool for HIT: results of a large Australian study
Morel-Kopp, Marie-Christine, Tan, Chee Wee, Brighton, Timothy A., McRae, Simon, Baker, Ross, Huyen Tran, Mollee, Peter, Kershaw, Geoffrey, Joseph, Joanne and Ward, Christopher (2012). Validation of whole blood impedance aggregometry as a new diagnostic tool for HIT: results of a large Australian study. Thrombosis and Haemostasis, 107 (3), 575-583. doi: 10.1160/TH11-09-0631
2012
Journal Article
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): The prospective international multicentre phase 2 PTLD-1 trial
Trappe, Ralf, Oertel, Stephan, Leblond, Veronique, Mollee, Peter, Sender, Monica, Reinke, Petra, Neuhaus, Ruth, Lehmkuhl, Hans, Horst, Heinz August, Salles, Gilles, Morschhauser, Franck, Jaccard, Arnaud, Lamy, Thierry, Leithäuser, Malte, Zimmermann, Heiner, Anagnostopoulos, Ioannis, Raphael, Martine, Riess, Hanno, Choquet, Sylvain and for the German PTLD Study Group and the European PTLD Network (2012). Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): The prospective international multicentre phase 2 PTLD-1 trial. The Lancet Oncology, 13 (2), 196-206. doi: 10.1016/S1470-2045(11)70300-X
2012
Journal Article
High dose methotrexate and extended hours high-flux hemodialysis for the treatment of primary central nervous system lymphoma in a patient with end stage renal disease
Mutsando, Howard, Fahim, Magid, Gill, Devinder S., Hawley, Carmel M., Johnson, David W., Maher, K. Gandhi, Marlton, Paula V., Mar Fan, Helen G. and Mollee, Peter N. (2012). High dose methotrexate and extended hours high-flux hemodialysis for the treatment of primary central nervous system lymphoma in a patient with end stage renal disease. American Journal of Blood Research, 2 (1), 66-70.
2012
Conference Publication
Outcomes and prognostic factors for patients with Acute Myeloid Leukemia admitted to the intensive care unit
Jackson, Kathryn A., Mollee, Peter, Morris, Kirk, Jackson, Dwane L., Kruger, Peter, Klein, Kerenaftali and Kennedy, Glen A. (2012). Outcomes and prognostic factors for patients with Acute Myeloid Leukemia admitted to the intensive care unit. 54th Annual Meeting and Exposition of the American Society of Hematology (ASH), Atlanta, GA, United States, 8-11 December 2012. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood.V120.21.3613.3613
2012
Conference Publication
Intensive Chemotherapy for Acute Myeloid Leukemia in Elderly Patients
Jackson, Kathryn A., Kennedy, Glen A., Mollee, Peter and Morris, Kirk (2012). Intensive Chemotherapy for Acute Myeloid Leukemia in Elderly Patients. 54th Annual Meeting and Exposition of the American Society of Hematology (ASH), Atlanta, GA, United States, 8-11 December 2012. Washington, DC, United States: American Society of Hematology.
2011
Conference Publication
Tissue microarray in DLBCL patients receiving R-CHOP chemo-immunotherapy shows survival benefit for coexpression of LMO2/BCL6
Keane, Colm, Shen, Linda, Han, Erica, Nourse, Jamie P, Lea, Rod, Mollee, Peter, Gill, Devinder S and Gandhi, Maher K (2011). Tissue microarray in DLBCL patients receiving R-CHOP chemo-immunotherapy shows survival benefit for coexpression of LMO2/BCL6. 53rd ASH Annual Meeting, San Diego, 10-13 December 2011. American Society of Hematology. doi: 10.1182/blood.v118.21.1585.1585
2011
Conference Publication
A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis
Mollee, Peter, Tiley, Campbell, Cunningham, Ilona, Moore, John, Prince, Miles, Cannell, Paul, Gibbons, Steve, Tate, Jill, Paul, Sanjoy and Gill, Devinder S (2011). A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis. 53rd ASH Annual Meeting, San Diego, 10-13 December 2011. American Society of Hematology. doi: 10.1182/blood.v118.21.3973.3973
2011
Conference Publication
ZAP-70 expression measured by quantitative PCR (QPCR) as a prognostic marker in chronic lymphocytic leukaemia (CLL)
Mollee, Peter, Banh, Raymond H., Cheung, Catherine, Saal, Russell, Chambers, Lynne, Pelly, Tennille and Gill, Devinder S (2011). ZAP-70 expression measured by quantitative PCR (QPCR) as a prognostic marker in chronic lymphocytic leukaemia (CLL). 53rd ASH Annual Meeting, San Diego, 10-13 December 2011. American Society of Hematology. doi: 10.1182/blood.v118.21.4602.4602
Supervision
Availability
- Associate Professor Peter Mollee is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Master Philosophy
Novel Radionuclide Tracers for Imaging in Amyloidosis
Principal Advisor
Other advisors: Associate Professor Colm Keane
-
Doctor Philosophy
Addressing frailty in older people with haematological malignancies
Associate Advisor
Other advisors: Associate Professor Emily Gordon, Dr Natasha Reid, Professor Ruth Hubbard
Media
Enquiries
For media enquiries about Associate Professor Peter Mollee's areas of expertise, story ideas and help finding experts, contact our Media team: